Belantamab mafodotin-associated corneal deposits on swept-source anterior segment optical coherence tomography andslit-lamp examination

A 78-year-old woman with relapsed IgG-kappa multiple myeloma developed bilateral blurred vision and monocular diplopia 21 days after starting the BelaPd regimen. Slit-lamp examination revealed bilateral subepithelial corneal deposits on direct illumination (Figure 1A, left eye) and retroillumination (Figure 1B, right eye), graded 2–3 according to the KVA scale⁽¹⁾. Anterior segment optical coherence tomography showed microcyst-like epithelial changes, predominantly in the peripheral and paracentral cornea (Figure 1C, right eye, and Figure 1D, left eye)^(2,3). The Bowman layer was preserved. The keratopathy resolved 2 months after belamaf was withheld.

REFERENCES

1. Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21(2):207–21.

2. Mencucci R, Cennamo M, Alonzo L, Senni C, Vagge A, Ferro Desideri L, et al. Corneal findings associated to belantamab-mafodotin (belamaf) use in a series of patients examined longitudinally by means of advanced corneal imaging. J Clin Med. 2022;11(10):2884.

3. Matsumiya W, Karaca I, Ghoraba H, Akhavanrezayat A, Mobasserian A, Hassan M, et al. Structural changes of corneal epithelium in belantamab-associated superficial keratopathy using anterior segment optical coherence tomography. Am J Ophthalmol Case Rep. 2021;23:101133.

Submitted for publication: June 8, 2026.
Accepted for publication: July 18, 2026.

Data Availability Statement: The datasets generated and/or analyzed during the current study are included in the manuscript.

Edited by

Editor-in-Chief: Newton Kara-Júnior

Associate Editor: Carlos Augusto Moreira Neto

Funding: This study received no specific financial support.

Disclosure of potential conflicts of interest: The authors declare no potential conflicts of interest.